The ethics of single blind trials

IRB Ethics and Human Research

Volumn 27, Issue 4, 2005, Pages 12-16

  Heckerling, Paul S ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27944496121     PISSN: 01937758     EISSN: None     Source Type: Journal    
DOI: 10.2307/3563956     Document Type: Article

References (48)

1. Rothman KJ, Michaels KB. The continuing unethical use of placebo controls. NEJM 1994;331:394-398;
2. Clark PI, Leaverton PE. Scientific and ethical issues in the use of placebo controls in clinical trials. Annual Review of Public Health 1994;15:19-38;
3. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments: I. Ethical and scientific issues. Annals of Internal Medicine 2000;133:455-463;
4. Simon R. Are placebo-controlled clinical trials ethical or needed when alternative treatment exists? Annals of Internal Medicine 2000;133:474-475;
5. Emanuel EJ, Miller PG. The ethics of placebo-controlled trials - a middle ground. NEJM 2001;345:915-919.
6. Evans M. Justified deception? The single blind placebo in drug research. Journal of Medical Ethics 2000;26:188-193.
7. Schulz KF, Grimes DA. Blinding in randomized trials: Hiding who got what. Lancet 2002;359:696-700.
8. Meinert CL, Tonascia S. Clinical Trials: Design, Conduct, and Analysis. New York: Oxford University Press, 1986.
9. See ref. 1, Temple and Ellenberg 2000.
10. Freedman B. Equipoise and the ethics of clinical research. NEJM 1987;317:141-145.
11. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000;283:2701-2711.
12. See ref. 1, Temple and Ellenberg 2000.
13. See ref. 1, Temple and Ellenberg 2000.
14. Vickers AJ, deCraen AJM. Why use placebos in clinical trials? A narrative review of the methodologic literature. Journal of Clinical Epidemiology 2000;53:157-161.
15. Meinert CL. Masked monitoring in clinical trials - blind stupidity? NEJM 1998;338:1381-1382.
16. See ref. 11, Meinert 1998.
17. See ref. 3, Schulz and Grimes 2002.
18. See ref. 4, Meinert and Tonascia 1986.
19. See ref. 7, Emanuel et al. 2000.
20. See ref. 3, Schulz and Grimes 2002.
21. See ref. 3, Schulz and Grimes 2002.
22. See ref. 3, Schulz and Grimes 2002.
23. Noseworthy JH, Ebers GC. Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on a randomized, placebo-controlled multiple sclerosis trial. Neurology 1994;44:16-20.
24. Schulz KF, Chalmers IA, Hayes RJ, Altman DG. Empirical evidence of bias: Dimensions of methodologic quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273: 408-412.
25. See ref. 7, Emanuel et al. 2000.
26. See ref. 3, Schulz and Grimes 2002; ref. 10, Vickers and DeCraen 2000.
27. See ref. 3, Schulz and Grimes 2002; ref. 10, Vickers and DeCraen 2000.
28. Halpern SD, Karlawish JHT, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002;288:358-362.
29. Clark PI, Leaverton PE. Scientific and ethical issues in the use of placebo controls in clinical trials. Annual Review of Public Health 1994;15:19-38;
30. Cassileth BR, Lusk EJ, Miller DS, Hurwitz S. Attitudes toward clinical trials among patients and the public. JAMA 1982;248:968-970;
31. Sugarman J, Kass NE, Goodman SN, Perentesis P, Fernandes P, Faden RR. What patients say about medical research. IRB: A Review of Human Subjects Research 1998;20:1-7;
32. Madsen SM, Holm S, Davidsen B, Munkholm P, Schlichting P, Rils P. Ethical aspects of clinical trials: The attitudes of participants in two non-cancer trials. Journal of Internal Medicine 2000;248:463-474.
33. See ref. 25, Sugarman et al. 1998.
34. See ref. 25, Cassileth et al. 1982.
35. See ref. 25, Clark and Leaverton 1994.
36. See ref. 25, Madsen et al. 2000.
37. Macklin R. The ethical problems with sham surgery in clinical research. NEJM 1999;341:992-996.
38. See ref. 25, Sugarman et al. 1998.
39. z. Kaptchuk TJ. Intentional ignorance: A history of blind assessment and placebo controls in medicine. Bulletin of the History of Medicine 1998;72:389-433.
40. Berman BM, Lao L, Langenberg P, Lee WL, Gilpin ALK, Hochberg MC. Effectiveness of acupuncture as adjunctive therapy in osteoarthritis of the knee: A randomized controlled trial. Annals of Internal Medicine 2004;141:901-910.
41. See ref. 7, Emanuel et al. 2000.
42. Ney PG, Collins C, Spensor C. Double blind: Double talk or are there better ways to do research. Medical Hypotheses 1986;21: 119-126;
43. Desbiens NA. Lessons learned from attempts to establish the blind in placebo-controlled trials of zinc for the common cold. Annals of Internal Medicine 2000;133:302-303;
44. Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: The success of blinding reported in a random sample of randomised, placebo controlled trials. BMJ 2004;328:432.
45. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. NEJM 2001;344: 1594-1602.
46. McPherson K, Britton AR, Wennburg JE. Are randomized controlled trials controlled? Patient preferences and unblind trials. Journal of the Royal Society of Medicine 1997;90:652-656;
47. Silverman WA, Altman DG. Patients' preferences and randomised trials. Lancet 1996;347:171-174.
48. Halpern SD. Evaluating preference effects in partially unblinded, randomized trials. Journal of Clinical Epidemiology 2003;56:109-115.